SCHEMBL2148995

SCHEMBL2148995

C1CCC(CC2CCNCC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.37
GBA1 P04062 1/20 0.37
ALDH1A1 P00352 1/20 0.35
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34
SLC6A1 P30531 2/20 0.33
GABRA5 P31644 2/20 0.33
GABRB2 P47870 2/20 0.33
SLC6A12 P48065 2/20 0.33
SLC6A11 P48066 2/20 0.33
SLC6A13 Q9NSD5 2/20 0.33
CHRM5 P08912 2/20 0.33
CYP1A2 P05177 1/20 0.33
ADRA2C P18825 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21940451 1.00 EPHX1 (0.37) EPHX1GBA1ALDH1A1NOS1NOS2
SCHEMBL8297763 1.00 EPHX1 (0.37) EPHX1GBA1ALDH1A1NOS1NOS2
SCHEMBL1692012 0.97 GBA1 (0.38) EPHX1GBA1MEN1MAPTKMT2A
Hydrochloric Acid SCHEMBL38665760 0.94 GBA1 (0.37) EPHX1GBA1SLC6A1GABRA5GABRB2
Piperazine SCHEMBL27857658 0.92 CXCR4 (0.37) EPHX1ALDH1A1NOS1NOS2MEN1
SCHEMBL21371574 0.89 ALDH1A1 (0.42) EPHX1ALDH1A1NOS1NOS2MEN1
SCHEMBL331996 0.88 GBA1 (0.42) GBA1NOS2SLC6A1GABRA5GABRB2
SCHEMBL1241237 0.85 GBA1 (0.41) GBA1SLC6A1GABRA5GABRB2SLC6A12
SCHEMBL7957882 0.83 CYP1A2 (0.44) EPHX1GBA1CYP1A2
SCHEMBL23070439 0.82 CHRM5 (0.43) EPHX1NOS1NOS2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US claimed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 EP claimed
EP-3331864-B1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2021-11-03 EP disclosed
WO-2019136244-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2019-07-11 WO disclosed
EP-2106423-B1 BITUMINOUS COMPOSITION WITH THERMOREVERSIBLE PROPERTIES TOTAL MARKETING SERVICES (FR) 2017-08-30 EP disclosed
US-9688646-B2 Process for producing N-methyl or N,N-dimethyl amines Lanxhou Institute of Chemical Physics, Chinese Academy of Sciences (CN) 2017-06-27 US disclosed
EP-1432420-B1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARM INC (US) 2011-07-13 EP disclosed
WO-2011072345-A1 ANTIFUNGAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2011-06-23 WO disclosed
US-7790744-B2 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 2010-09-07 US disclosed
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2010-08-26 US disclosed
US-4391812-A ANTIINFLAMMATORY AGENTS MERCK & CO., INC. (US) 1983-07-05 US disclosed
US-4342873-A MICROBIOCIDES MERCK & CO., INC. (US) 1982-08-03 US disclosed
US-4342872-A ANTIMICROBIAL AGENTS MERCK & CO., INC. (US) 1982-08-03 US disclosed
EP-0049902-A2 Novel thiazolo(3,2-a)pyrimidines, derivatives thereof, processes for production thereof, and pharmaceutical use thereof TEIJIN LIMITED (JP) 1982-04-21 EP disclosed
US-4308382-A ANTIINFLAMMATORY AGENTS STERLING DRUG INC. (US) 1981-12-29 US disclosed
EP-0024356-A1 Pharmaceutical composition for treating a condition exhibiting pain, fever, and inflammation comprising 2-(substituted piperidinomethyl) propane- and propene nitriles MERCK & CO. INC. (US) 1981-03-04 EP disclosed
US-4254131-A Treatment of pain, fever, and inflammation with compositions containing 2-(substitutedpiperidinomethyl)propane and propene nitriles MERCK & CO., INC. (US) 1981-03-03 US disclosed
US-4247700-A MICROBIOCIDES MERCK & CO., INC. (US) 1981-01-27 US disclosed
US-4216326-A Intermediates for preparing anti-inflammatory phenyl-lower-alkylamines STERLING DRUG INC. (US) 1980-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R EPHX1 297/4885GBA1 2652/4885ALDH1A1 1731/4885
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 EPHX1 1692/4885GBA1 1424/4885ALDH1A1 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.